Portal de Periódicos da CAPES

INTERMACS Database for Durable Devices for Circulatory Support: First Annual Report

2008; Elsevier BV; Volume: 27; Issue: 10 Linguagem: Inglês

10.1016/j.healun.2008.07.021

1557-3117

James K. Kirklin, David C. Naftel, Lynne Warner Stevenson, Robert L. Kormos, Francis D. Pagani, Marissa A. Miller, K.L. Ulisney, James B. Young,

Cardiac Valve Diseases and Treatments

INTERMACS has completed the analysis of first full year of data on FDA-approved durable VADs. To date, nearly all approved devices are pulsatile volume-displacement pumps. As newer rotary pumps gain FDA approval, they will become a vital part of the INTERMACS experience and analyses. Overall survival after device implant exceeds 70% at 6 months, but is superior with isolated LVAD compared with bi-VAD support. The initial "strategy" at implant has no discernible effect on survival, and the frequency with which initial strategy changes within 3 to 6 months supports the notion that planning mechanical support around a "final decision" regarding transplantation may provide a convenient metric for reimbursement but is flawed as a patient management tool given the occasional profound salutary effect that mechanical circulatory support device interventions can have on the very comorbidities that drive the choice of therapy.